Delsie Braganza

Delsie joined the Focal Point Research team in 2011 and has been an invaluable asset for our clients. With her strong regulatory and quality assurance background, she is able to help clients understand the Canadian and US requirements, set targets to achieve compliance, and attain their goals to get products to market.

Delsie is able to audit facilities, set up and maintain GMP compliant facilities, develop strong quality management systems, and co-ordinate successful Health Canada inspections. In addition to this, Delsie oversees all regulatory compliance reviews and submissions made to Health Canada and the US FDA.

Delsie obtained an Honours Bachelor of Science (Hons. B. Sc.) in Pharmaceutical Chemistry from the University of Toronto, Post-Graduate Certificate in Pharmaceutical Regulatory Affairs and Quality Operations (RAQ) from Seneca College and Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society (RAPS).

When she’s not learning something new, Delsie loves spending time with family, going on road trips or long walks, and swimming.

Articles

If you would like to be added to our newsletter, please send an email to mail@focalpointresearch.net with the subject line ‘Receive FPR Newsletter’.

174 Substances Added to the Non-Domestic Substances List (NDSL)

Apr 15, 2026

On March 24th, a significant update was published in the Canada Gazette, Part I, Volume 160, Number 14: an Order Amending the Non-domestic Substances List (NDSL). This latest order officially adds 174 substances to the NDSL. For companies manufacturing or importing...

NNHPD Launches Dedicated Landing Page for Non-prescription Drugs

Apr 15, 2026

The Natural and Non-prescription Health Products Directorate (NNHPD) has officially launched a new, centralized landing page designed specifically for Non-prescription Drugs (NPDs). This initiative aims to streamline the regulatory process by providing clearer, more...

Federal Plastics Registry: Reporting Deadlines Updated

Apr 13, 2026

On March 14, 2026, the Government of Canada published an amended Section 46 Notice in the Canada Gazette, postponing Phase 2 and 3 reporting deadlines under the Federal Plastics Registry (FPR) for 2024-2026. Phase 1 reporting remains mandatory. Producers of packaging,...

CARB launches 2025 Technical Assessment for Personal Fragrance Products VOC Compliance

Apr 13, 2026

California Air Resources Board is conducting its 2025 Personal Fragrance Products Technical Assessment to evaluate the feasibility of meeting the 50% VOC limit using current and emerging technologies. All required data submissions must be provided by March 31, 2026,...

New Jersey enacts PFAS ban impacting cosmetics

Apr 13, 2026

The State of New Jersey has enacted legislation prohibiting the sale of cosmetics containing intentionally added PFAS under ‘Protecting Against Forever Chemicals Act’, effective two years after the law comes into force. Cosmetic products with only technically...

FDA Issues Final rule on Nation Drug Code (NDC) format

Apr 13, 2026

The US FDA has issued a final rule adopting a uniform 12-digit format for the NDC, which uniquely identifies drugs marketed in the US. Currently, FDA-assigned NDCs are 10 digits and may appear in several different formats. The rule will take effect on March 7, 2033....

Health Canada updates Acceptable Intake limits for Nitrosamine impurities

Apr 13, 2026

Health Canada has updated its list of established Acceptable Intake (AI) limits for nitrosamine impurities (Appendix 1), now available online. The update includes the addition of N-nitroso-dabigatran etexilate imide as a new impurity with a corresponding AI limit,...

New SNAc provisions added for two substances on Canada’s DSL

Apr 13, 2026

ECCC and Health Canada have announced updates to the DSL in Canada Gazette, Part I, introducing Significant New Activity (SNAc) provisions for two substances used in consumer products, including cosmetics: 2-ethylhexyl 2-ethylhexanoate and Cyclohexylamine. The new...

NNHPD clarifies review prioritization for NHP licence applications

Apr 13, 2026

The NNHPD is currently experiencing a high volume of NHP licence applications and has formalized how applications will be assigned for review under its workload management approach. Applications will now be reviewed on when prioritization was requested instead of the...

Updates to the Cosmetic Notification Form

Apr 6, 2026

Health Canada recently announced significant updates to the Cosmetic Notification Form (CNF) and the Guide for Cosmetic Notifications. These changes introduce a ‘flexible approach’ to how companies disclose fragrance allergens, balancing consumer safety with a...

« Older Entries

“Focal Point Research has consistently and professionally looked after regulatory and quality issues of our brand for years. Through a courteous and knowledgeable team, they have managed to navigate us through an ever changing regulatory landscape while maintaining our interests, and allowed us to correctly distribute and sell within Canada.”

“I have truly enjoyed working with you over the last 8 years! You and your team have been an amazing resource for me. I have always been impressed by the knowledge and professionalism of everyone at Focal Point, which is a true testament to your leadership.”

Connect With Us

The Focal Point Research team is ready to help with all of your scientific and regulatory needs. Our team has the experience and expertise you need to see your product to market and we are eager to help you.

Focal Point Research Inc.

6700 Century Ave., Suite 319

Mississauga, ON L5N 6A4

Delsie Braganza

Jennifer Porter, BA Psychology, MBA – President & CEO

Articles

If you would like to be added to our newsletter, please send an email to mail@focalpointresearch.net with the subject line ‘Receive FPR Newsletter’.

Connect With Us